News|Articles|November 16, 2026

Cefazolin Possibly Superior, Probably Safer than Cloxacillin for MSSA Bacteremia

Cefazolin evidenced non-inferiority and probable superiority, as well as greater safety compared to antistaphylococcal penicillins for methicillin-susceptible S aureus bacteremia, in meta-analysis of direct comparison trials.

Cefazolin was found safer, and at least non-inferior and probably superior to cloxacillin or flucloxacillin in treating methicillin-susceptible S aureus bacteremia (MSSA), in a meta-analysis of the 2 randomized clinical trials that have directly compared the drug classes.1 "Taken together with the other advantages of cefazolin, including its longer half-life, tolerability and potential for use in patients with penicillin allergy, we believe the data supports cefazolin being preferred for adults with MSSA bacteremia," declare Todd Lee, MD, MPH, Division of Infectious Diseases, Department of Medicine, McGill University, Montréal, Canada, and colleagues.

In accompanying commentary, Michihiko Goto, MD, MS, Center for Access & Delivery Research and Evaluation (CADRE), Iowa City VA Health Care System, Iowa City, IA, credits the randomized trials and meta-analysis for addressing a long standing absence of comparative data that has left clinicians wondering whether cefazolin "is at least as good."2

"Few questions in clinical infectious diseases have been debated for so long with so little reliable clinical data as the choice of ß-lactam for MSSA bacteremia," Goto remarked.

The two trials that compared the classes are the French Cloxacillin vs Cefazolin for MSSA Bacteremia (CloCeBa) trial, and the International S aureus Network Adaptive Platform (SNAP) trial, together comprising approximately 1600 patients. 3,4

Goto points out a particular difference in the trial designs: the SNAP trial enrolled only patients with penicillin-resistant MSSA, while the CloCeBa included patients with MSSA irrespective of penicillin susceptibility.The noninferiority of cefazolin in the CloCeBa trial, he notes, was therefore demonstrated in a population that theoretically disadvantages it.

"This is a stronger result than the pooled numbers alone convey, and it matters in practice because many clinical laboratories do not routinely report penicillin susceptibility for S aureus," Goto observed.

Lee and colleagues conducted the bayesian meta-analysis of outcomes of the drug classes in both trials to ascertain a log odds ratio (OR) of 90-day mortality, treatment discontinuation for adverse events, and acute kidney injury data. They determined an OR of 0.84 (95% CI, 0.59-1.28), or 95.5% probability of cefazolin noninferiority; and an 81.0% probability of superiority.

What You Need to Know

In a Bayesian meta-analysis of the CloCeBa and SNAP trials (about 1600 patients), cefazolin had a 95.5% probability of being noninferior to cloxacillin or flucloxacillin for 90-day mortality in MSSA bacteremia, and an 81.0% probability of being superior (OR 0.84; 95% CI, 0.59-1.28).

Cefazolin was also safer, with fewer treatment discontinuations due to adverse events (OR 0.25; 99.9% probability of superiority) and fewer acute kidney injuries (OR 0.54; 98.4% probability of superiority).

The investigators say the evidence supports making cefazolin the preferred treatment for adults with MSSA bacteremia, while commentator Michihiko Goto, MD, MS, argues that future research should target high-inoculum infections such as endocarditis and whether the findings apply to nafcillin and oxacillin, rather than another head-to-head trial.

Cefazolin demonstrated 99.9% probability of superiority for fewer treatments discontinued due to adverse events (OR 0.25 [0.13-0.48]); and 98.4% probability of superiority with fewer acute kidney injuries (OR 0.54 [0.25-0.97]).

A subgroup analysis of mortality in patients with endocarditis (8.4% of SNAP patients) appeared comparable with the overall results, with 94.4% probability of cefazolin noninferiority (OR <1.2). In a subgroup of the CloCeBa trial participants with S aureus type A blaZ gene, the investigators found 20% (6 of 30) mortality at 90 days with cefazolin and 7.1% (2 of 28) with cloxacillin.

Genotyping and phenotyping are pending from the SNAP trial, which Lee and colleagues indicate should help in more precisely determining the magnitude and relevance of the inoculum effect.

"Given the size of the existing evidence base, another head-to-head trial of the primary question is unlikely to be the best use of resources," Goto indicated."Investment is better directed toward the remaining questions, such as high-inoculum infections (eg endocarditis), and the generalizability of these findings to nafcillin and oxacillin."

References
1. Lee TC, Tong SYC, Davis JS, et al. Cefazolin vs cloxacillin for methicillin-susceptible S aureus bacteremia. A meta-analysis of 2 randomized clinical trials. JAMA Netw Open. 2026; 9(11):e2643836. doi:10.1001/jamanetworkopen.2026.43836.
2. Goto M. Cefzolin vs antistaphylococcal penicillins for methicillin-susceptible Staphyloccus aureus bacteremia—convergence of observational and randomized evidence. JAMA Netw Open. 2026; 9(11):e2643842. doi:10.1001/jamanetworkopen.2026.43842.
3. Burdet C, Saïdani N, Dupieux C, et al. CloCeBa Study Group. Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial. Lancet. 2025; 406(10517):2349-2359. doi:10.1016/S0140-6736(25)01624-1.
4. Lee TC, Barina LA, Walls G, et al. Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group. Cefazolin for methicillin-susceptible Staphylococcus aureus bacteremia. N Engl J Med. 2026; 394(23):2329-2339. doi:10.1056/NEJMoa2506905.

Related to this article

FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.